tbuckley/cabot-search huggingface dataset:
Abstract P4-18-03: Measuring what is important to patients in clinical trials: Hearing the patient's voice
Authors: PA Spears, P Devine, S Finestone
Journal: Cancer Research (2017)

Abstract Patients who participate in clinical trials are important to clinical research and contribute to the advancement of medical discoveries. However, typical clinical trials do not always capture information that is important to patients: how they feel, function and survive. The only way to accurately measure how a patient feels or functions is to ask them. This can be done through the administration of health related questionnaires that are filled out by the patient without interpretation from anyone else; these are referred to as Patient Reported Outcomes (PROs). Although, PRO assessments have been used in clinical trials for the past 30 years through the collection of global quality of life (QOL) and later health related QOL (HR-QOL) measurements, the information has been too broad and has not been precise enough to use in drug approvals, descriptive drug label information or to inform other patients. There is an effort to change the paradigm of PRO assessment to measure the information most relevant to patients in clinical trials. This includes measuring treatment toxicity, symptom burden and physical function. This is relevant information that other patients want to know about a specific treatment for a specific disease to help them in their treatment decision making. The voice of the patient is critical to assess these items, through PRO measurements. In order to ensure that PRO questionnaires are filled out during a clinical trial, there are ways to make them more acceptable to patients by involving patients in their development (what questions are asked/how many questions are asked/when they are given to patients/how they are given to patients). Patients can inform study teams on the acceptability, understandability and relevance of the questions being asked. Patients can be a key contributor to clinical trial development by identifying the questions that are most important to them and the best way to ask these questions during a clinical trial. Patient advocacy and educational organizations like Cancer Information &amp; Support Network (CISN) are advocating for changes in PRO collection in clinical trials. Based on information collected from many survivors, caregivers and advocates, a patient-centric clinical trial development model will be proposed. The model includes the involvement of patients as key stakeholders early in clinical trial development to incorporate PROs into clinical trials that are acceptable for patients to complete and the outcomes are meaningful and matter to future patients. Citation Format: Spears PA, Devine P, Finestone S. Measuring what is important to patients in clinical trials: Hearing the patient's voice [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-18-03.
Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lymphoproliferative Malignancies: Phase 1 Results.
Authors: Steven M. Horwitz, Julie M. Vose, Ranjana Advani, Kamalesh Sankhala, Swaminathan Padmanabhan, Paul A. Hamlin, Andy Chen, Jasmine M Zain, Steven Fruchtman, Owen A O'Connor
Journal: Blood (2009)
Abstract PD8-01: Race and age differences in PAM50 biomarker status in the Carolina breast cancer study
Authors: MA Troester, X Sun, EH Allott, C-K Kit, L Thorne, M Mathews, SM Cohen, J Geradts, E Kirk, Y Li, Z Hu, W Robinson, KA Hoadley, K Reeder-Hayes, S Earp, AF Olshan, LA Carey, CM Perou
Journal: Cancer Research (2017)

Abstract Background: African American breast cancer patients have lower relative frequency of hormone receptor (HR)-positive/HER2-negative disease and higher subtype-specific mortality. However, few population-based studies have RNA-based subtyping data, and racial differences in the biology of HR-positive/HER2-negative tumors are not well understood. Methods: Using data and biospecimens from the Carolina Breast Cancer Study (CBCS) Phase 3 (2008-2013), we classified approximately 1,000 invasive breast cancers according to PAM50 subtype and two risk of recurrence scores (ROR-P and ROR-PT). Relative frequency of Luminal A, Luminal B, Her2-enriched, and Basal-like subtypes and ROR scores (low/medium/high) were compared by race (blacks vs. whites) and age (≤50 years vs. &amp;gt;50 years), overall and among HR-positive/HER2-negative cases. Results: Black women of all ages had significantly higher relative frequency of Basal-like breast cancer (36 and 31% in blacks vs. 18 and 15% in whites; younger and older, respectively) and lower frequency of Luminal A breast cancer (26 and 34% in blacks vs. 43 and 52% in whites; younger and older, respectively). Frequency of Luminal B and HER2-enriched breast cancer did not vary by race or age. Among clinically HR-positive, HER2-negative cases, Luminal A subtype comprised only half of the cases among black women, and was significantly less common than among white women (51% vs 60% in whites, p&amp;lt;0.05). Black women with HR-positive/HER2-negative disease also had significantly higher ROR scores (ROR-P medium or high 82% vs. 66% in whites, p=0.01; ROR-PT medium or high 85% vs. 69% in whites, p&amp;lt;0.01). Conclusions: Multi-gene assays highlight disparities in frequency of aggressive, poorer prognosis tumor subtypes and implicate differences in tumor biology as an important contributor to mortality disparities among HR-positive/HER2-negative patients. Citation Format: Troester MA, Sun X, Allott EH, Kit C-K, Thorne L, Mathews M, Cohen SM, Geradts J, Kirk E, Li Y, Hu Z, Robinson W, Hoadley KA, Reeder-Hayes K, Earp S, Olshan AF, Carey LA, Perou CM. Race and age differences in PAM50 biomarker status in the Carolina breast cancer study [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr PD8-01.
Therapeutic Response to Azacitidine (AZA) In Patients with Secondary Myelodysplastic Syndromes (sMDS) Enrolled In the AVIDA Registry
Authors: Mikkael A. Sekeres, Mohit Narang, Rami S. Komrokji, Jaroslaw P Maciejewski, Alan F. List, Thomas K. Street, Arlene S. Swern, Kristen A. Sullivan, David L. Grinblatt
Journal: Blood (2010)
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study
Authors: Chloe Orkin, Edwin DeJesus, Moti Ramgopal, Gordon Crofoot, Peter Ruane, Anthony LaMarca, Anthony Mills, Bernard Vandercam, Joseph de Wet, Jürgen Rockstroh, Adriano Lazzarin, Bart Rijnders, Daniel Podzamczer, Anders Thalme, Marcel Stoeckle, Danielle Porter, Hui C Liu, Andrew Cheng, Erin Quirk, Devi SenGupta, Huyen Cao
Journal: The Lancet HIV (2017)
The AKT/mTOR/P70S6K/4EB-P1 Signaling Pathway Is Activated in a Subset of Multiple Myeloma Patients and Correlates with High Serum Levels of Beta2-Microglobulin
Authors: Tommasina Guglielmelli, Susanna Cappia, Emilia Giugliano, Roberta Merlini, Elisa Bacillo, Francesca Gay, Paola Berchialla, Dario Gregori, Mauro Papotti, Antonio Palumbo, Giuseppe Saglio
Journal: Blood (2008)
PP84. ENDOSCOPIC RESECTION OF A THIRD VENTRICULAR PILOCYTIC ASTROCYTOMA WITH PILOMYXOID FEATURES IN AN 86-YEAR OLD PATIENT: CASE REPORT AND REVIEW OF THE LITERATURE
Authors: Mr Jignesh Tailor, Dr Anand Pandit, Ms Clementina Calabria, Mr Jose Pedro Lavrador, Dr Istvan Bodi, Prof Keyoumars Ashkan, Mr Christopher Chandler, Mr Sanjeev Bassi, Mr Bassel Zebian
Journal: Neuro-Oncology (2017)

OBJECTIVE: Pilocytic astrocytomas are extremely rare in octagenarians especially those occurring in the third ventricle. They are similar histopathologically to pilomyxoid astrocytomas but the latter are more aggressive. We report the case of an 86-year old patient presenting with confusion and lethargy secondary to a third ventricular lesion causing obstructive hydrocephalus. The lesion was approached endoscopically and sub-totally resected. Histologically the lesion was classified as a pilocytic astrocytoma with pilomyxoid features. The patient made a full recovery and did not require a shunt. MATERIALS AND METHODS: Case report with pictures and video of the operative approach as well as discussion of the imaging sequences and histology, and review of the literature. RESULTS: Sub-total resection of the tumour was achieved using a monoportal image-guided endoscopic approach. Normal cerebrospinal fluid circulation was restored and a shunt was not required. Histologically, the mass was confirmed to be a pilocytic astrocytoma with pilomyxoid features. The patient made a full recovery with resolution of her symptoms. No such case has been reported in the literature to date. CONCLUSION: This is the first report of a third-ventricular pilocytic astrocytomas with pilomyxoid features in an octogenarian. The endoscopic approach in the case at hand, allowed safe direct visualisation and sub-total resection of the lesion, providing histological diagnosis to guide management and obviating the need for a shunt. The minimally invasive nature of the approach translated into full recovery, despite the age of the patient.
Abstract P5-09-01: Plasma osteoprotegerin and the risk of breast cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers
Authors: J Kotsopoulos, L Oden, M Akbari, C Singer, P Sun, L Salmena, S Narod
Journal: Cancer Research (2017)

Abstract This abstract was withdrawn by the authors.
Patterns of Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer
Authors: Antonio Di Meglio, Nancy U. Lin, Rachel A. Freedman, William T. Barry, Eric P. Winer, Ines Vaz-Luis
Journal: Journal of the National Comprehensive Cancer Network (2017)

Background: When monitoring patients with metastatic breast cancer (mBC), the optimal strategies for imaging and utilization of tumor markers (TM) are uncertain. Patients and Methods: We used a retrospective cohort of 302 patients with de novo mBC treated from 2000 to 2012 at Dana-Farber Cancer Institute to describe the type and timing of imaging and TM testing during the first line of treatment (baseline, first, and subsequent testing). Results: At baseline, all patients had staging scans, with increasing use of PET/PET-CT (17.5% from 2000–2002; 40.3% from 2009–2012). PET/PET-CT was used by itself in only 12.5% of cases. Overall, 30.1% of patients, of whom 80.2% had no neurologic symptoms, underwent central nervous system (CNS) screening; 78.2% of patients had baseline TM testing. Over the course of treatment, 23.5% of patients had TM retested once a month or more. Time-to-first reimaging varied by disease site (hazard ratios for shorter time-to-first reimaging [95% CI] vs bone: brain, 4.27 [1.46–12.50]; liver, 2.19 [1.39–3.46]; lung, 2.75 [1.66–4.57]), but was not associated with tumor subtype or baseline TM testing, regardless of test results. First reimaging was prompted by an elevation in TM in only 1.4% of cases. There was weak correlation between frequency of imaging and TM tests (r=0.33; R2=0.11; P<.001). Discussion: Over time, we found an increased utilization of more sophisticated imaging staging techniques, such as PET/PET-CT scan, which was mostly requested in addition to other radiographic studies. CNS evaluations were frequently performed to screen asymptomatic patients. TM testing was often ordered, both at baseline and after treatment initiation. However, patterns of imaging utilization, although appropriately influenced by clinicopathologic factors such as disease site, did not appear to be impacted by TM testing. Conclusions: Studies focused on optimizing disease monitoring, including better integration of TM testing with imaging, are encouraged.
Conformal phased surfaces for wireless powering of bioelectronic microdevices
Authors: Devansh R. Agrawal, Yuji Tanabe, Desen Weng, Andrew Ma, Stephanie Hsu, Song-Yan Liao, Zhe Zhen, Zi-Yi Zhu, Chuanbowen Sun, Zhenya Dong, Fengyuan Yang, Hung Fat Tse, Ada S. Y. Poon, John S. Ho
Journal: Nature Biomedical Engineering (2017)
Comment on Hong et al. Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease. Diabetes Care 2013;36:1304–1311
Authors: Søren Søgaard Lund, Yan Gong
Journal: Diabetes Care (2013)

In a carefully conducted randomized clinical trial (RCT), Hong et al. (1) report that 3 years of metformin treatment was associated with significantly lower cardiovascular (CV) risk after an additional 2 years of postdrug follow-up versus glipizide (a sulfonylurea) in 304 type 2 diabetic (T2D) patients with coronary artery disease. The study is unique because UK Prospective Diabetes Study (UKPDS), the landmark study creating metformin’s cardioprotective reputation, did not report CV outcomes comparing metformin versus sulfonylurea (2). Thus, the study by Hong et al. is probably the first report of CV outcomes comparing metformin versus sulfonylurea from a dedicated CV trial. The lack of previous such comparison is remarkable, and Hong et al. should be applauded for their contribution.

Some caveats may apply, however. First, …
New prognostic loci related to the survival of patients with advanced non-small cell lung cancer receiving chemotherapy: A genome-wide association study.
Authors: Young Joo Lee, Kyong-Ah Yoon, Jungnam Joo, Donghoon Lee, Ji-Youn Han, Jin Soo Lee
Journal: Journal of Clinical Oncology (2012)

e18119 Background: We investigated prognostic significance of genetic variants identified by genome-wide association study (GWAS) for the patients with advanced non-small cell lung cancer (NSCLC). Methods: Among the patients included in our previous GWAS paper for lung cancer risk, we selected 348 patients with stage IV NSCLC, who had started chemotherapy in May 2002 through December 2005 at the National Cancer Center Hospital, and had the follow-up data available. After applying quality control criteria, the association of 271,817 genotyped SNPs with overall survival was analyzed by the Cox proportional hazard regression model adjusted with known prognostic factors using the bootstrap resampling procedure. Results: Overall, the median age of patients was 56 years, 64.9% were female, 67.2% were never smokers, and 80.4% had adenocarcinoma; 73.0% received platinum-based chemotherapy and 73.6 % received EGFR-TKIs. The median survival time (MST) for all patients was 25 months. A total of 23 SNPs with MAF of &gt;0.05 were selected using a cut-off minimum p-value of &lt;5x10 -5 (either in additive or dominant models) in at least 70% of a thousand bootstrap samples. Those SNPs were known to be located in the genomic coding region of the FAM154A, EGF, NCOA2, CDH8, ANKS1A, DLST, VGCNL1, SLC35D2, and THSD7B. Carrying a variant genotype of rs1571228 SNP located on the FAM154A, for example, was significantly associated with better overall survival with MST of 29.6 months for those with AG/GG (n=144/30) genotypes vs. 21.5 months for those with AA (n=173) genotype under the dominant model (hazard ratio of 0.52 [95% CI, 0.42-0.67], p = 2.03 x 10 -7 ). This association remained consistent in a subgroup of patients who received platinum-based chemotherapy (n= 254, p = 1.69 x 10 -6 ) or EGFR-TKIs (n = 256, p = 9.04 x 10 -6 ). Conclusions: Genetic variants at multiple loci were found to be prognostically important for patients with advanced NSCLC, which warrants further investigation into its biological relevance and clinical implication.
Cidofovir Is Safe and Effective in the Treatment of Adenoviral Infection in Pediatric Hematopoietic Stem Cell Transplantation.
Authors: Usman Yusuf, Gregory Hale, Paul Woodard, Ely Benaim, Kimberly Kasow, Edwin Horwitz, Wing Leung, Deo Srivastava, Rupert Handgretinger, Randy Haden
Journal: Blood (2004)
Pediatric Palliative Care—A Shared Priority
Authors: Jennifer W. Mack
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Abstract A12: Developing PDeX (Patient Derived Explant) to determine the basis for response to AR-directed therapeutics
Authors: Ayesha Shafi, Matthew Schiewer, Renee de Leeuw, Peter McCue, Ruth Birbe, Leonard Gomella, Costas Lallas, Edouard Trabulsi, Ganesh Raj, Karen Knudsen
Journal: Clinical Cancer Research (2016)

Abstract Prostate cancer (PCa) is the most common non-cutanenous cancer and the second leading cause of cancer-related death in American men. Androgen receptor (AR) is a hormone-activated transcription factor that plays an important role in both the development and progression of PCa. Androgen deprivation therapy is a common first-line therapy. However, many patients become resistant to such therapy and the tumor recurs. Thus, there is a vital need for the development of novel, more effective drugs. One major hurdle in this aspect is the lack of adequate preclinical models. Current models do not effectively recapitulate the heterogeneity and the microenvironment of human PCa tumors hindering the ability to accurately predict therapeutic response. Our lab has generated a method to culture patient tumors ex vivo termed patient derived explant (PDeX). This approach maintains the integrity of the native tumor microenvironment, tumor tissue morphology, and molecular signaling. Intriguingly, our PDEX model can be targeted with various therapeutic agents or lentiviral-based shRNAs to determine specific responses on individual tumor growth. Furthermore, with this model we can quantitatively assess drug efficacy on numerous parameters (i.e. AR levels, Ki67 staining, apoptosis screening). Data to be discussed will assess the variances in response to AR-directed therapeutics and underlying mechanisms of action. In addition, we can potentially identify clinically relevant subpopulations of patients and molecularly profile their cultured tissue to uncover new pathways for therapeutic intervention. Thus, the PDeX model allows for a comprehensive evaluation of individual tumors in their native microenvironment to ultimately develop more effective therapies. Citation Format: Ayesha Shafi, Matthew Schiewer, Renee de Leeuw, Peter McCue, Ruth Birbe, Leonard Gomella, Costas Lallas, Edouard Trabulsi, Ganesh Raj, Karen Knudsen. Developing PDeX (Patient Derived Explant) to determine the basis for response to AR-directed therapeutics. [abstract]. In: Proceedings of the AACR Special Conference: Patient-Derived Cancer Models: Present and Future Applications from Basic Science to the Clinic; Feb 11-14, 2016; New Orleans, LA. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(16_Suppl):Abstract nr A12.
HDAC Inhibitors Lead to Significant Survival Benefit in a Novel Fusion Protein TBLR1-Rarα Induced Murine Promyelocytic Leukemia Model
Authors: Shouyun Li, Shuang Liu, Shuying Chen, Yirui Chen, Ying Wang, Liping Chen, Zheng Tian, Haiyan Xing, Kejing Tang, Yingxi Xu, Qing Rao, Min Wang, Jianxiang Wang
Journal: Blood (2016)
Phase II Multicenter Study of the Safety and Efficacy of Single-Agent Lenalidomide in Subjects with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Follow-up Analysis of the NHL-003 Study.
Authors: Pier Luigi Zinzani, Julie M Vose, Myron S. Czuczman, Craig Reeder, Corinne Haioun, Jonathan Polikoff, Herve Tilly, Dennis Pietronigro, Annette Ervin-Haynes, Ju Li, Thomas E. Witzig
Journal: Blood (2012)
Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia
Authors: Sunniyat Rahman, Michael Magnussen, Theresa E. León, Nadine Farah, Zhaodong Li, Brian J. Abraham, Krisztina Z. Alapi, Rachel J. Mitchell, Tom Naughton, Adele K. Fielding, Arnold Pizzey, Sophia Bustraan, Christopher Allen, Teodora Popa, Karin Pike-Overzet, Laura Garcia-Perez, Rosemary E. Gale, David C. Linch, Frank J. T. Staal, Richard A. Young, A. Thomas Look, Marc R. Mansour
Journal: Blood (2017)
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
Authors: M.V. Dieci, C. Criscitiello, A. Goubar, G. Viale, P. Conte, V. Guarneri, G. Ficarra, M.C. Mathieu, S. Delaloge, G. Curigliano, F. Andre
Journal: Annals of Oncology (2015)
Abstract IA04: The carcinogenic potential of bacterial biofilms
Authors: Cynthia L. Sears
Journal: Cancer Research (2017)

Abstract The colonic microbiome is hypothesized to contribute to CRC pathogenesis and to potentially act as an initiator of colon oncogenesis, in part via induction of specific mucosal pro-carcinogenic immune responses. Both we and others have presented data from experimental models implicating specific bacteria in colon carcinogenesis. Enterotoxigenic Bacteriodes fragilis (ETBF), Escherichia coli containing the pks island [E. coli (pks)] and Fusobacterium nucleatum represent colon carcinogenic bacteria strongly implicated to date in both experimental models and human disease. To further address the links between the microbiota and human colon cancer, we are prospectively studying the microbial associations of human CRC together with parameters of mucosal immunity. Paired surgical CRC samples and normal colon mucosa are studied along with colon biopsies (right and left) of healthy controls undergoing screening colonoscopy. We have presented data demonstrating that sporadic colon tumors located proximal to the hepatic flexure are characterized by invasive polymicrobial biofilms that extend to normal colon tissue far distant from the tumor. In contrast, biofilm formation is infrequent in colon tumors distal to the hepatic flexure and in the mucosa of colonoscopy controls. Biofilm formation in the human colon is associated with changes in E-cadherin, IL-6 induction, activation of pStat3, colonic epithelial cell proliferation as well as polyamine metabolism. These data suggest biofilm formation promotes pro-carcinogenic immune and epithelial signaling in the human colon. We have further tested our hypothesis that biofilm formation contributes to colon carcinogenesis by examining surgically-removed colons from individuals with Familial Adenomatous Polyposis (FAP) who are destined, as Apc+/- heterozygotes, to develop colon cancer. In contrast to sporadic CRC, early stage FAP patients display patchy biofilm formation throughout the colon and the bacterial composition of FAP-associated colon biofilms differs. Murine studies support synergistic induction of colon tumor formation by select biofilm bacterial members. Together our studies provide additional support for the hypothesis that the microbiota and, specifically, biofilms are an environmental contributor to CRC pathogenesis. Citation Format: Cynthia L. Sears. The carcinogenic potential of bacterial biofilms. [abstract]. In: Proceedings of the AACR Special Conference on Colorectal Cancer: From Initiation to Outcomes; 2016 Sep 17-20; Tampa, FL. Philadelphia (PA): AACR; Cancer Res 2017;77(3 Suppl):Abstract nr IA04.